Thromboxane A synthase-independent production of 12- hydroxyheptadecatrienoic acid, a BLT2 ligand

Journal of Lipid Research

Volumn 54, Issue 11, 2013, Pages 2979-2987

  Matsunobu, Takehiko ^a   Okuno, Toshiaki ^a,b   Yokoyama, Chieko ^c   Yokomizo, Takehiko ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

12 HHT; Cyclooxygenase; Eicosanoid; Mass spectrometry; TxAS

Indexed keywords

12 HYDROXYHEPTADECATRIENOIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FATTY ACID; ICOSANOID; PROSTAGLANDIN E2; PROSTAGLANDIN G2; THROMBOXANE B2; THROMBOXANE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

12-HHT; CYCLOOXYGENASE; EICOSANOID; MASS SPECTROMETRY; TXAS;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENZYME INHIBITORS; FATTY ACIDS, UNSATURATED; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HUMANS; LIGANDS; MICE; MICE, INBRED C57BL; PROSTAGLANDIN H2; RECEPTORS, LEUKOTRIENE B4; THROMBOXANE B2; THROMBOXANE-A SYNTHASE;

EID: 84886073716     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M037754     Document Type: Article

References (33)

1. John, H., K. Cammann, and W. Schlegel. 1998. Development and review of radioimmunoassay of 12-S-hydroxyheptadecatrienoic acid. Prostaglandins Other Lipid Mediat. 56: 53-76. (Pubitemid 28453268)
2. Smith, W. L., Y. Urade, and P. J. Jakobsson. 2011. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem. Rev. 111: 5821-5865.
3. Simmons, D. L., R. M. Botting, and T. Hla. 2004. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56: 387-437. (Pubitemid 39096597)
4. Vincent, J. E., F. J. Zijlstra, and H. van Vliet. 1980. Determination of the formation of thromboxane B2 (TxB2), 12L-hydroxy-5,8,10 heptadecatrienoic acid (HHT) and 12L-hydroxy-5,8,10,14 eicosatrienoic acid (HETE) from arachidonic acid and of the TxB2:HHT, TxB2:HETE and (TxB2 +HHT):HETE ratio in human platelets. Possible use in diagnostic purposes. Prostaglandins Med. 5: 79-84. (Pubitemid 10093018)
5. Frohberg, P., G. Drutkowski, and I. Wobst. 2006. Monitoring eicosanoid biosynthesis via lipoxygenase and cyclooxygenase pathways in human whole blood by single HPLC run. J. Pharm. Biomed. Anal. 41: 1317-1324. (Pubitemid 43775884)
6. Beving, H., S. Eksborg, R. Nordlander, P. Olsson, and U. Olsson. 1990. Effects on cyclo-oxygenase of low and high dose aspirin. Thromb. Res. 59: 227-235. (Pubitemid 20289935)
7. Best, L. C., P. B. Jones, M. B. McGuire, and R. G. Russell. 1980. Thromboxane B2 production and lipid peroxidation in human blood platelets. Adv. Prostaglandin Thromboxane Res. 6: 297-299.
8. Greenwald, J. E., M. S. Alexander, M. Van Rollins, L. K. Wong, and J. R. Bianchine. 1981. Argentation thin layer chromatography of arachidonic acid metabolites isolated from human platelets. Prostaglandins. 21: 33-39. (Pubitemid 11178151)
9. Hall, E. R., and H. H. Tai. 1981. Purification of thromboxane synthetase and evidence of two distinct mechanisms for the formation of 12-L-hydroxy-5,8,10-heptadecatrienoic acid by porcine lung microsomes. Biochim. Biophys. Acta. 665: 498-503. (Pubitemid 11011389)
10. Stuart, M. J., and J. B. Allen. 1982. Arachidonic acid metabolism in the neonatal platelet. Pediatrics. 69: 714-718. (Pubitemid 12114421)
11. Sadowitz, P. D., B. N. Setty, and M. Stuart. 1987. The platelet cyclooxygenase metabolite 12-L-hydroxy-5, 8, 10-hepta-decatrienoic acid (HHT) may modulate primary hemostasis by stimulating prostacyclin production. Prostaglandins. 34: 749-763.
12. Sweeney, F. J., M. J. Pereira, J. D. Eskra, and T. J. Carty. 1987. The use of 12-hydroxyheptadecatrienoic acid (HHT) as an HPLC/spectrophotometric marker for cyclooxygenase pathway activity in resident rat peritoneal cells. Prostaglandins Leukot. Med. 26: 171-177. (Pubitemid 17024770)
13. Shimizu, T., K. Kondo, and O. Hayaishi. 1981. Role of prostaglandin endoperoxides in the serum thiobarbituric acid reaction. Arch. Biochem. Biophys. 206: 271-276. (Pubitemid 11102029)
14. Sellers, M. M., and J. N. Stallone. 2008. Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure. Am. J. Physiol. Heart Circ. Physiol. 294: H1978-H1986.
15. Izumo, T., G. Suzuki, Z. Chen, Y. Fujii, and C. Kamei. 1999. Effects of certain cerebral circulation activating drugs on regional cerebral blood flow in rats. Methods Find. Exp. Clin. Pharmacol. 21: 279-283. (Pubitemid 29283884)
16. Okuno, T., Y. Iizuka, H. Okazaki, T. Yokomizo, R. Taguchi, and T. Shimizu. 2008. 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J. Exp. Med. 205: 759-766. (Pubitemid 351549875)
17. Yokomizo, T. 2011. Leukotriene B4 receptors: novel roles in immunological regulations. Adv. Enzyme Regul. 51: 59-64.
18. Iizuka, Y., T. Okuno, K. Saeki, H. Uozaki, S. Okada, T. Misaka, T. Sato, H. Toh, M. Fukayama, N. Takeda, et al. 2010. Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. FASEB J. 24: 4678-4690.
19. Yokoyama, C., T. Yabuki, M. Shimonishi, M. Wada, T. Hatae, S. Ohkawara, J. Takeda, T. Kinoshita, M. Okabe, and T. Tanabe. 2002. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation. 106: 2397-2403. (Pubitemid 35244744)
20. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 108: 193-199.
21. Yokoyama, C., A. Miyata, K. Suzuki, Y. Nishikawa, T. Yoshimoto, S. Yamamoto, R. Nusing, V. Ullrich, and T. Tanabe. 1993. Expression of human thromboxane synthase using a baculovirus system. FEBS Lett. 318: 91-94. (Pubitemid 23057044)
22. Kita, Y., T. Takahashi, N. Uozumi, and T. Shimizu. 2005. A multiplex quantitation method for eicosanoids and platelet-activating factor using column-switching reversed-phase liquid chromatographytandem mass spectrometry. Anal. Biochem. 342: 134-143. (Pubitemid 40805637)
23. Hamberg, M., J. Svensson, and B. Samuelsson. 1974. Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc. Natl. Acad. Sci. USA. 71: 3824-3828.
24. Hamberg, M., J. Svensson, T. Wakabayashi, and B. Samuelsson. 1974. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc. Natl. Acad. Sci. USA. 71: 345-349.
25. Isobe, Y., M. Arita, S. Matsueda, R. Iwamoto, T. Fujihara, H. Nakanishi, R. Taguchi, K. Masuda, K. Sasaki, D. Urabe, et al. 2012. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J. Biol. Chem. 287: 10525-10534.
26. Hamberg, M., and B. Samuelsson. 1967. Oxygenation of unsaturated fatty acids by the vesicular gland of sheep. J. Biol. Chem. 242: 5344-5354.
27. Woodward, D. F., R. L. Jones, and S. Narumiya. 2011. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 63: 471-538.
28. Narumiya, S. 2003. Prostanoids in immunity: roles revealed by mice deficient in their receptors. Life Sci. 74: 391-395. (Pubitemid 37357068)
29. Watanabe, K., S. Ito, and S. Yamamoto. 2008. Studies on membraneassociated prostaglandin E synthase-2 with reference to production of 12L-hydroxy-5,8,10-heptadecatrienoic acid (HHT). Biochem. Biophys. Res. Commun. 367: 782-786.
30. Yu, I. S., S. R. Lin, C. C. Huang, H. Y. Tseng, P. H. Huang, G. Y. Shi, H. L. Wu, C. L. Tang, P. H. Chu, L. H. Wang, et al. 2004. TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood. 104: 135-142.
31. Bui, P., S. Imaizumi, S. R. Beedanagari, S. T. Reddy, and O. Hankinson. 2011. Human CYP2S1 metabolizes cyclooxygenase- and lipoxygenase-derived eicosanoids. Drug Metab. Dispos. 39: 180-190.
32. Verstraete, M., and P. Zoldhelyi. 1995. Novel antithrombotic drugs in development. Drugs. 49: 856-884.
33. De Clerck, F., J. Beetens, D. de Chaffoy de Courcelles, E. Vercammen, E. Freyne, and P. A. Janssen. 1989. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule. Prog. Clin. Biol. Res. 301: 567-572. Technology Technology Technology Technology Technology Technology